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INTRODUCTION: 
Urinary tract infection (UTI) is a common and painful 
human illness affecting all age groups and sexes, 
fortunately, is rapidly responsive to modern antibiotic 
therapy.
1
 But now a days, treatment of UTI has supposed 
to be a problem to the clinician due to emergence of 
resistance strains of bacteria to various antimicrobials used 
over the years. There has been a growing rate of resistance 
among common urinary tract pathogens, such as 
Escherichia coli, to traditional antimicrobial therapies 
including the "gold standard" trimethoprim-
sulfamethoxazole (TMP-SMX). Consequently, 
fluoroquinolone antimicrobial agents have taken on an 
expanding management role for UTIs. In fact, the recent 
Infectious Diseases Society of America clinical 
management guidelines for UTI recommend 
fluoroquinolones as first-line therapy for uncomplicated 
UTI in areas where resistance is likely to be of concern. 
Fluoroquinolones have demonstrated high bacteriologic 
and clinical cure rates, as well as low rates of resistance, 
among most common uropathogens.
2
 Fluoroquinolones 
have been recommended as the drugs of choice for the 
empirical treatment of uncomplicated and complicated 
urinary tract infections (UTIs) caused by trimethoprim-
sulfamethoxazole-resistant uropathogens. 
3
Among the 
floroquinolones, pfloxacin is commonly prescribed for the 
treatment of UTI. 
Alkalinisation of urine by disodium hydrogen citrate 
solution is a common practice for symptomatic 
improvement by most of the physician. Urinary 
alkalinising agents such as sodium citrate have been given 
by mouth to relieve the pain of cystitis caused by UTI.
4
 
So, during treatment of UTI, fluoroquinolones along with 
alkalinising agents are used simultenously. But whether 
the alkalinisation of urine increases the efficacy of 
fluoroquinolones in treatment of UTI is not known clearly.  
On this background, this study was carried out to assess 
the effect of alkalinisation of urine on the efficacy of 
pefloxacin, a newer fluoroquinolone in the treatment of 
uncomplicated UTI. 
 
MATERIALS AND METHODS:- 
ETHICAL CONSIDERATIONS: 
The study protocol, informed consent form (in Bengali, 
Hindi & English) and case report form (CRF) were 
submitted to the ethics committee of R.G.Kar Medical 
College & Hospital, Kolkata West Bengal for approval. 
Subject recruitment commenced only after approval was 
obtained. Written informed consent was taken from each 
participant. Illiterate individuals gave their fingerprint (left 
thumb impression) instead of signature in the presence of 
an appropriate witness. 
SUBJECT SELECTION CRITERIA:  
The subjects who had willingly participated were enrolled 
on the basis of inclusion and exclusion criteria. Patients 
with uncomplicated UTI (sensitive to pefloxacin 
irrespective of causative organism) aged between 18 to 60 
years of either sex were included in the study. Where 
pregnant and lactating mothers, any haematological 
diseases, diabetes mellitus, any malignancy, any urinary 
tract abnormality, any liver/kidney disorders, known 
allergy to flouroquinolones and history of any other 
antibiotic intake within 2 weeks prior to study and during 
study period, were excluded from the study.   
 STUDY SETTING  
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The study was conducted in the Department of Medicine, 
R. G. Kar Medical College & Hospital, Kolkata, West 
Bengal.  
Screening: Through General Medicine OPD of 
R.G.K.M.C.  
Recruitment and Drug dispensing: Through General 
Medicine OPD of R.G.K.M.C.  
Data compilation and Statistical analysis: In Department 
of Pharmacology, R.G.K.M.C. 
STUDY DESIGN:  
The current study was designed as a prospective, 
interventional, randomized, assessor blind, fixed dose with 
two parallel treatment groups and unicentric.   
Study Period: The study was conducted from March 
2012-December 2012. 
Regulatory Considerations: 
Since the study medication (Pefloxacin) was already 
marketed in India at the time of study inception, no 
separate regulatory approval from the Drugs Controller 
General of India was sought. 
Study Groups and Randomization: 
A random number table generated by computer in blocks 
of 100. The large block size reduced the risk of allocation 
bias. The study coordinator was the only person with 
access to the randomization. According to the 
randomization sequence subjects fulfilling the selection 
criteria were received either pefloxacin 400 mg twice daily 
orally for consecutive 5 days or pefloxacin in doses of  400 
mg BD and alkalinising agent (disodium hydrogen citrate 
1.4gm/5 ml) 10 ml thrice daily orally for consecutive 5 
days. 
Blinding: Study was designed as assessor-blind study. The 
identity of the study group was blinded to the assessor 
physician (microbiologist and pathologist).  
METHODS 
After recruitment, a detailed medical history was taken 
followed by thorough clinical examination which included 
both general and systemic examination. This was followed 
by examination of urine i.e. routine urine examination (pH, 
pus cells, R.B.C, epithelial cells, albumin/ cast), culture 
and sensitivity. Routine laboratory investigations (Hb%, 
TC, DC, ESR, FBS, PPBS urea, creatinine, Liver function 
test) and imaging (straight x-ray abdomen/K.U.B, 
intravenous urography, Ultrasonography) were done in all 
subjects. . The patients with UTI were screened from OPD 
with one/more of the following criteria: dysurea, increased 
frequency of urination, decreased amount of urine passed, 
high coloured urine, fever, supra-pubic tenderness, 
palpable bladder. Following the above selection criteria 70 
patients were included in the study. 
After screening, the patients who fulfilled the selection 
criteria except the culture sensitivity report (which would 
be available after 72 hours) were randomized and called 
for baseline visit on the same day.  
The first dose of study medication was given in this 1
st
 
day. A urine specimen was obtained at baseline for routine 
analysis and for culture /sensitivity testing before 
administration of the drug.  
On next visit at 8
th
 day of treatment clinical evaluation was 
done as well as bacteriological tests were repeated.  
Bacteriological and clinical effectiveness were reassessed 
on 15
th
 day, and a repeat course of pefloxacin was given to 
those patients whose urine report showed persistence of 
organism.  
On 22
nd
 day urine samples were recollected from these 
patients and reassessed.        
Statistical analysis:  
Data was processed and analyzed at the Department of 
Pharmacology, R.G.K.M.C, Kolkata. Analysis was done 
only after CRF of the last subject was in, data had been 
entered, and the computer database cleaned and locked. 
Statistical analysis was performed using graph pad-instat-3 
software.  
Dichotomous events were analyzed by using the Person’s 
two sided Chi-square comparison Statistical significance 
was defined as P-value<0.05. 
RESULTS AND ANALYSIS: 
All the 70 cases were confirmed as UTI on the basis of 
urine culture of the patients Among the 70 patients in the 
study, female were more sufferer in UTI than male 
(female: male- 64:6 ). Their mean age was 29.8 years and 
mean body weight was 48.52 kg.  
Result of culture of urine: 
Urine culture reports were analysis. The various organism 
isolated from the urine culture were tabulated in table 1 
and figure 1. 
Table 1: Shows distribution of causative organisms of UTI 
Causative organism  Numbers Percentage (%) 
Escherichia coli 58 82.86% 
Klebsiella 6 7.14% 
Proteus 3 4.28% 
Pseudomonas 2 2.85% 
Ureaplasm 
urealyticum 
1 1.42% 
 
Sales
E.coli
klebsiella
Proteus 
Pseudomonas
Ureaplasm
Figure 1: Shows distribution of causative organisms of 
UTI
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Table 2: shows analysis of the clinical and bacteriological findings: 
                                                                
SYMPTOMS 
NO. OF 
CASES 
URINARY 
FINDINGS 
 
+VE -VE 
 
MICROSCOPICAL & 
BACTERIOLOGICAL OBSERVATIONS 
IN POSITIVE  CASES 
 
P B P+B P+C B+C P+B+C 
 
1.dysurea 
 
2.increasedfrequency of  
   Urination 
 
3.dysurea + increased   
   Frequency 
 
4.dysurea + fever 
 
5.fever + frequency 
 
5.dysurea+frequency+fever 
 
7.pain 
 
8.high colour urine 
20 
 
12 
 
 
14 
 
 
7 
 
4 
 
3 
 
4 
 
6 
16           4 
 
10            2 
 
 
14           0 
 
 
 7             0 
 
3             1 
 
3              0   
           
2             2 
 
4             2 
  1      1       3          1          1           9 
 
  1      1       1           -         1            7 
 
 
  -        -       1          -         2            11 
 
 
  -        1      2          1         1             2 
 
  -         -      -           -         1             2 
 
  -        1       -          -          1             1 
 
  -         -       -          -          -              2 
 
  1         -      1          -          -              2 
TOTAL 70 59          11 3       4        8       2           7           36 
  
P= PUS CELLS, B= BACTERIA, C = CULTURE 
RESULT OF TREATMENT: 
Clinical and bacteriological evaluation were done again 
after 5 days of therapy. It  was seen that  the 35 cases 
treated with pefloxacin alone were completely cured 
(100%) but patients those were received pefloxacin along 
with alkali solution (35 patients) the treatment success 
were very low; that was only 16(45.71%) that was 
statistically significant (p<0.001). Cases were designated 
bacteriologically as eradicated, when urine samples were 
found to be sterile and persistent when the urine specimens 
showed bacteria microscopically or growth on culture or 
both. 
RESULT OF RETREATMENT: 
Those cases which were not eradicated by pefloxacin plus 
disodium hydrogen citrate solution were again subjected to 
consecutive 5 days therapy with pefloxacin alone. It is 
seen that all the cases which failed to show eradication by 
treatment with pefloxacin with disodium hydrogen citrate 
solution could be eradicated by another consecutive 5 days 
therapy with pefloxacin alone.  
DISCUSSION: 
Urinary tract infection is common ailment affecting 
predominantly females between ages of 20 to 45 years. In 
this study female: male ratio is 10.67: 1 which 
corroborates well with the text book figure though 
incidence varies at different stages of life. 
The present comparative study of bacteriological and 
clinical efficacy showed 100% of patients were relieved of 
symptoms and signs when pefloxacin alone were used, 
whereas only 45.71% of patients receiving pefloxacin + 
disodium hydrogen citrate solution showed eradication and 
clinical cure with a p value of <0.001 that was significant. 
Of the 35 patients in the group treated with disodium 
hydrogen citrate solution + pefloxacin, only 16 (45.71%) 
patients were found to be cured and the rest  patients were 
then subjected to a further treatment of 5 days with 
pefloxacin alone  (400 mg BD) and showed complete 
eradication of the organism. 
Therefore, we can say that antimicrobial efficacy of 
pefloxacin showed diminution of action in the presence of 
alkalinisation of urine. It is known that gastrointestinal 
absorption of pefloxacin is reduced by antacids containing 
salts of magnesium, aluminium or calcium only.
5 
However, any mention of pharmacokinetic or 
pharmacodynamic drug-drug interaction between 
pefloxacin and disodium hydrogen citrate is not found in 
the literature.  
Though appropriate explanation for this diminution of 
action of pefloxacin can not be found, but there are few 
facts to be mentioned. It is known that, antibacterial used 
to treat UTI need to be excreted in adequate concentration 
in urine.
4 
Unlike other fluoroquinolones major pathway of 
excretion of pefloxacin is non-renal.
6 
It is known that, pefloxacin has been metabolized in liver 
to N-Desmethyl pefloxacin (Norfloxacin). Norfloxacin is 
least soluble at a urinary pH of 7.5.
7 
it was observed the 
presence of crystals of fluoroquinolones particularly of 
norfloxacin in the alkaline urine.
8
 So, this may also occur 
following administration of pefloxacin, as its major 
metabolite is norfloxacin. 
Thus, fewer amounts of active metabolites of pefloxacin 
(Norfloxacin) present in urine is further reduced by 
crystalisation and precipitation of Norfloxacin in alkaline 
urine 
8
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Due to the above reasons, the concentration of pefloxacin 
and its major metabolite, norfloxacin present in alkaline 
urine may be less than the required minimum inhibitory 
concentration. 
The present study had some limitations  
 The study did not include placebo group so that it is 
impossible to determine absolute level of efficacy.  
 It was not possible to measure the blood concentration 
of both drugs.  
 The trial was not double blind study.  
CONCLUSION  
In spite of the above limitation, it can be said that 
pefloxacin should not be co-prescribed with alkalinizing 
agents for the treatment of UTI. Further studies with large 
sample size will required for further evaluation.
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